Published in Springerplus on September 15, 2016
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol (2014) 4.82
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2013) 4.46
New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology (2014) 3.14
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis (2012) 2.41
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
EASL recommendations on treatment of hepatitis C 2014. J Hepatol (2014) 1.81
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol (2011) 1.44
The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology (2011) 1.10
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol (2011) 1.08
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut (2014) 1.06
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother (2011) 1.05
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther (2014) 0.90
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology (2014) 0.90
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther (2014) 0.85
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol (2016) 0.81
Daclatasvir for the treatment of chronic hepatitis C. Expert Opin Pharmacother (2015) 0.79
Daclatasvir: A Review in Chronic Hepatitis C. Drugs (2016) 0.78